Post by centralcoastinvestor on Mar 14, 2018 15:03:49 GMT -5
I thought to myself, should I be doing something more productive with my time? Am I in too deep? Do I care too much? The answers: perhaps, yes and yes. Because I do care, I will continue to post. I have some thoughts to share regarding recent events:
The ongoing recapitalization of MannKind. Mike C. and his executive team continue to clean up the balance sheet. It is somewhat painful for long term shareholders as it causes dilution, but it is better than closing the doors. I think Mike C. has done a good job of laying out what tasks need to be done for the future of the company and has consistently checked them off. It isn’t easy what Mike C. is trying to do. However, I really like where he is taking the company.
The hiring of David Kendall, MD. This is a really wonderful hire by Mike C. Why would David come over to MannKind from a very stable and good paying job at an established BP? And why would Mike C. indicate that the hiring of David was the final key to his executive team? My opinion is this. Even with all of his accomplishments over his career, David like Mike, wants to change the way diabetes is treated worldwide. As Mike C. often states, with all of the money spent on research and all of the discoveries over the past 20 years, the treatment of diabetes has not not changed or improved much, especially when you consider outcomes. This is true because treating to lower the A1c has been limited because of the fear of hypoglycemia. I think David wants to make a lasting impact on really improving the lives of diabetics. And that is very good for MannKind. David mentioned that there were 60 trials over the years for Afrezza, many of these results were never released. (I don’t know why.). It is my opinion and hope that David will repackage this information along with the new STAT trial results to share with the diabetic establishment and potentially to seek another improved label change from the FDA. I think David has connections that until now, MannKind has never had.
This post is already too long. So I will close with this. I have been perplexed as to why someone like myself (I am not a genius) along with all of the other longs and current Afrezza users can understand the life changing potential of Afrezza, but so few others seem to. Is it possible that some company or someone with a great deal of financial resources will also recognize this potential and invest in a big way to finally help Afrezza succeed? Why hasn’t an Elon Musk or a Bill Gates stepped up? I find this fascinating but do not have an answer.
As I have said before, I truly believe Afrezza will ultimately succeed. But it has sure taken a lot longer for that to happen than I would have ever dreamt. Stay Long My Friends
The ongoing recapitalization of MannKind. Mike C. and his executive team continue to clean up the balance sheet. It is somewhat painful for long term shareholders as it causes dilution, but it is better than closing the doors. I think Mike C. has done a good job of laying out what tasks need to be done for the future of the company and has consistently checked them off. It isn’t easy what Mike C. is trying to do. However, I really like where he is taking the company.
The hiring of David Kendall, MD. This is a really wonderful hire by Mike C. Why would David come over to MannKind from a very stable and good paying job at an established BP? And why would Mike C. indicate that the hiring of David was the final key to his executive team? My opinion is this. Even with all of his accomplishments over his career, David like Mike, wants to change the way diabetes is treated worldwide. As Mike C. often states, with all of the money spent on research and all of the discoveries over the past 20 years, the treatment of diabetes has not not changed or improved much, especially when you consider outcomes. This is true because treating to lower the A1c has been limited because of the fear of hypoglycemia. I think David wants to make a lasting impact on really improving the lives of diabetics. And that is very good for MannKind. David mentioned that there were 60 trials over the years for Afrezza, many of these results were never released. (I don’t know why.). It is my opinion and hope that David will repackage this information along with the new STAT trial results to share with the diabetic establishment and potentially to seek another improved label change from the FDA. I think David has connections that until now, MannKind has never had.
This post is already too long. So I will close with this. I have been perplexed as to why someone like myself (I am not a genius) along with all of the other longs and current Afrezza users can understand the life changing potential of Afrezza, but so few others seem to. Is it possible that some company or someone with a great deal of financial resources will also recognize this potential and invest in a big way to finally help Afrezza succeed? Why hasn’t an Elon Musk or a Bill Gates stepped up? I find this fascinating but do not have an answer.
As I have said before, I truly believe Afrezza will ultimately succeed. But it has sure taken a lot longer for that to happen than I would have ever dreamt. Stay Long My Friends
/production/original_573352236.gif)
things that we all know nothing about.
